PDSB

PDS Biotechnology Corporation

5.45 USD
+0.03 (+0.55%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

PDS Biotechnology Corporation stock is down -0.73% since 30 days ago. The next earnings date is Mar 26, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 8 February’s closed higher than January. In the last 1 Unusual Options Trades, there were 1 PUT.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
16 Jan 15:08 16 Aug, 2024 7.50 PUT 99 0

About PDS Biotechnology Corporation

PDS Biotechnology Corporation focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials.